BioAdaptives to Acquire Xycota Biosciences to Pursue the Potential of At Home Psilocybin Treatment
The proposed acquisition uses preferred stock rather than cash, with financing conditional and existing shareholders facing dilution.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioAdaptives (BDPT) signed a definitive agreement to acquire Xycota Biosciences, adding preclinical drug programs targeting brain and nervous-system conditions. The transaction remains unclosed, carries no cash purchase price and terminates automatically if not closed by June 30, 2027.
Consideration includes Economic Preferred stock representing 40% of post-issuance voting power and economic ownership. Separate Voting Preferred stock carries 51% of voting power, initially for CEO James E. Keener, with transfer to Xycota members upon specified events. Investors agreed to provide $150,000 after closing in four tranches, subject to spending certification; no funding has been received. Preferred stock and convertible notes will dilute holders. Xycota's lead candidate, XYCO-02, targets mild PTSD with low-dose oral psilocybin intended for use without hallucinogenic effects; its clinical dose remains undetermined.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Definitive acquisition agreement would add Xycota's preclinical brain and nervous-system drug-development programs to BioAdaptives.
- Major point. Forward-looking: it has not happened yet and may not happen.$150,000 in post-closing investor funding is agreed in four tranches, subject to spending certification. 48% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Up to $800,000 over 36 months comprises a $400,000 milestone-triggered call and separate $400,000 optional investment. 2.5× market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Up to $160,000 is provided for reporting and spin-off costs, with conditions on spin-off funding. 51% of market cap
- Minor pointNo cash purchase price is payable for the proposed acquisition.
2 minor points
- Minor pointXYCO-02 targets mild PTSD; the pipeline also includes XYCO-01 for frontotemporal dementia and early preclinical research in traumatic brain injury and cognitive aging.
- Minor pointLow-dose psilocybin improved recognition memory in a rat model of Fragile X syndrome in a 2026 study.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Economic Preferred stock due within 20 business days after closing represents 40% of post-issuance voting power and economic ownership.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Voting Preferred stock carries 51% of voting power, initially for Keener, transferring to Xycota members upon specified events.
- Moderate point. Forward-looking: it has not happened yet and may not happen.12-month convertible notes carry a 10% original issue discount and 10% one-time interest charge; conversion dilutes holders.
- Minor pointClosing conditions remain pending; the agreement terminates automatically if closing has not occurred by June 30, 2027.
- Minor pointNo funding received; none is payable before closing, and the financing amounts are not unrestricted closing cash.
3 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.$400,000 milestone-triggered call depends on a Control Event and Rule 144 issuer conditions.
- Minor pointXYCO-02's clinical dose remains undetermined; the supporting animal study evaluated neither PTSD nor human subjects.
- Minor pointXYCO-01's FDA Orphan Drug Designation request is on file but has not been granted.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LAS VEGAS, NV AND SHERIDAN, WY / ACCESS Newswire / November 5, 2026 / BioAdaptives, Inc. (OTCID:BDPT) has signed a definitive agreement to acquire Xycota Biosciences, LLC, a preclinical biotechnology company pursuing an ambitious goal: an oral psilocybin treatment that patients could take at home without hallucinogenic effects. The agreement, dated October 29, 2026, would bring Xycota's CNS drug-development programs into BioAdaptives. The transaction has not closed and remains subject to closing conditions.
An opportunity to change how treatment reaches patients
Xycota's thesis reaches beyond the molecule to how treatment could fit into everyday life. If a low-dose oral medicine can deliver meaningful benefit without requiring prolonged supervised psychedelic sessions, it could reduce the time and logistical burden on patients and create a more scalable treatment model. For BioAdaptives stockholders, the proposed acquisition offers participation in developing that possibility, beginning with mild post-traumatic stress disorder (PTSD). Safety, efficacy and suitability for at-home use would need to be established through clinical development and regulatory review.
The scientific starting point is a 2026 study published in Neuropsychopharmacology and co-authored by Xycota Chief Scientific Officer Marvin S. Hausman, M.D. Repeated low-dose psilocybin improved recognition memory in a rat model of Fragile X syndrome, with findings supporting a role for BDNF/TrkB signaling, a pathway involved in neuroplasticity. For Xycota, that finding provides a rationale to investigate whether low-dose treatment can produce clinical benefit without hallucinogenic effects. The study did not evaluate PTSD or human subjects; translating the animal findings into an effective medicine remains the central development challenge.
The lead candidate, XYCO-02, is low-dose oral psilocybin intended to be sub-perceptual, with the clinical dose still to be determined. Xycota's pipeline also includes XYCO-01, an exosome-formulated psilocin candidate for frontotemporal dementia, and early preclinical research in traumatic brain injury and cognitive aging. An FDA Orphan Drug Designation request for XYCO-01 is on file and has not been granted.
"We are pursuing a question with significant implications for patients: can a low, sub-perceptual dose of psilocybin and/or psilocin engage the BDNF/TrkB pathway involved in neuroplasticity without hallucinogenic effects? If clinical studies support that approach, it could open a path toward a treatment for PTSD that fits more readily into patients' daily lives," said Marvin S. Hausman, M.D., Co-Founder and Chief Scientific Officer of Xycota.
Transaction and operational structure
At closing, Xycota would become a wholly owned subsidiary of BioAdaptives and continue under its existing executive and scientific leadership, including Co-Founders Brad Listermann, Chief Executive Officer, and Dr. Hausman. The acquisition consideration is payable to the Xycota members who are parties to the agreement, rather than to Xycota itself. No cash purchase price is payable.
BioAdaptives is obligated to issue Economic Preferred stock within 20 business days after closing, representing
The agreement provides for separate Xycota bank accounts under its management's signatory control and contractual restrictions on using Xycota intellectual property or dedicated cash for BioAdaptives' legacy nutraceutical obligations or parent overhead. BioAdaptives' existing nutraceutical operations would continue separately. A possible spin-off is subject to the agreement; the Xycota founders and their affiliates would receive no interest in that spin-off entity.
Financing and stockholder terms
No funding has been received under the agreement, and none is payable before closing. After closing, the investors have agreed to provide
Funding is through 12-month convertible notes carrying a
"This agreement gives stockholders a defined path into CNS biotechnology, with Xycota operating separately, funding tied to closing and milestones, and full terms in our Form 8-K. We will report each step promptly," said James E. Keener, Chief Executive Officer of BioAdaptives.
About the companies
BioAdaptives, Inc. (OTCID:BDPT) is a nutraceutical supplier. Xycota Biosciences, LLC is a preclinical CNS company led by Brad Listermann and Marvin S. Hausman MD. Lead Scientist Viviana Trezza, Ph.D., is Associate Professor at Roma Tre University. Psilocybin and psilocin are Schedule I controlled substances in the United States. No Xycota product has been tested in a company-sponsored human study or approved by any regulator.
Forward looking statements
This release contains forward-looking statements about closing, financing, control changes, a possible spin-off and Xycota's programs. Actual results may differ materially. Closing and funding depend on conditions that may not be satisfied. Issuance and conversion of preferred stock and notes will dilute stockholders. Xycota's candidates are preclinical, involve controlled substances and require regulatory and ethics approvals that may be delayed or denied. Animal findings may not translate to humans. A Control Event or spin-off may never occur. The stock is thinly traded and may be volatile. Readers should review the Form 8-K filed November 4, 2026 and the company's other SEC filings. Statements speak only as of this date, with no update obligation except as required by law. This release is not an offer to sell securities.
INVESTOR & MEDIA CONTACT
BioAdaptives, Inc:
Drew@BioAdaptives.com
702-659-8829
X - @BioAdaptivesInc
Xycota:
Brad Listermann
brad@xycota.com.
SOURCE: BioAdaptives, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What will BioAdaptives pay to acquire Xycota Biosciences?
BioAdaptives will pay no cash purchase price; consideration payable to participating Xycota members includes Economic Preferred stock representing 40% of total voting power and economic ownership immediately after issuance. The stock is due within 20 business days after closing.
When must the BioAdaptives acquisition of Xycota close?
The agreement terminates automatically if closing has not occurred by June 30, 2027. The transaction has not closed and remains subject to closing conditions.
How would Xycota operate within BioAdaptives after the acquisition?
Xycota would become a wholly owned subsidiary under its existing executive and scientific leadership. Separate bank accounts would remain under its management's signatory control, with contractual restrictions on using Xycota intellectual property or dedicated cash for BioAdaptives' legacy nutraceutical obligations or parent overhead.
What would a BioAdaptives nutraceutical spin-off mean for Xycota's founders?
Xycota's founders and their affiliates would receive no interest in a possible nutraceutical spin-off entity. Existing nutraceutical operations would continue separately, and any spin-off is subject to the agreement.
What events would transfer BioAdaptives' Voting Preferred stock to Xycota members?
The Voting Preferred stock transfers to Xycota members upon specified regulatory or clinical milestones, a nutraceutical spin-off, or another transfer event defined in the agreement. It is initially issuable to BioAdaptives CEO James E. Keener, and its voting rights are distinct from economic ownership.